| Sanofi-Aventis (Suisse) SA - VaxigripTetra, Suspension pour injection dans une seringue pré-remplie | | 66427 | | 08 | | VaxigripTetra | | Suspension pour injection dans une seringue pré-remplie | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 01.08.2024 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Thailand/8/2022 (H3N2)-like: derived from A/California/122/2022, SAN-022) 15 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, wilde type (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus souche B/Phuket/3073/2013-like: B/Phuket/3073/2013, wilde type (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. | | Packungsbestandteile | | | |
|
